These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23271969)

  • 1. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.
    Mohan GS; Li W; Ye L; Compans RW; Yang C
    PLoS Pathog; 2012; 8(12):e1003065. PubMed ID: 23271969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
    Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 5. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
    Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
    Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
    Blaney JE; Marzi A; Willet M; Papaneri AB; Wirblich C; Feldmann F; Holbrook M; Jahrling P; Feldmann H; Schnell MJ
    PLoS Pathog; 2013; 9(5):e1003389. PubMed ID: 23737747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.
    Liu Y; Ye L; Lin F; Gomaa Y; Flyer D; Carrion R; Patterson JL; Prausnitz MR; Smith G; Glenn G; Wu H; Compans RW; Yang C
    J Infect Dis; 2018 Nov; 218(suppl_5):S545-S552. PubMed ID: 29893888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.
    Pallesen J; Murin CD; de Val N; Cottrell CA; Hastie KM; Turner HL; Fusco ML; Flyak AI; Zeitlin L; Crowe JE; Andersen KG; Saphire EO; Ward AB
    Nat Microbiol; 2016 Aug; 1(9):16128. PubMed ID: 27562261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
    Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
    PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge.
    Liu Y; Ye L; Lin F; Gomaa Y; Flyer D; Carrion R; Patterson JL; Prausnitz MR; Smith G; Glenn G; Wu H; Compans RW; Yang C
    Sci Rep; 2018 Jul; 8(1):11193. PubMed ID: 30046140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
    Mellquist-Riemenschneider JL; Garrison AR; Geisbert JB; Saikh KU; Heidebrink KD; Jahrling PB; Ulrich RG; Schmaljohn CS
    Virus Res; 2003 Apr; 92(2):187-93. PubMed ID: 12686428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.